Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020
November 05, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Strengthened Formulary Access for Xtampza® ER, Including Exclusive National Medicare Part D Win – – Generated $34.2 Million in Cash Flow from Operations – – Adjusted EBITDA of...
Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain Medicine
October 26, 2020 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
October 22, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...
Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation
September 30, 2020 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Appoints Rita Balice-Gordon to its Board of Directors
September 25, 2020 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference
September 14, 2020 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference
September 09, 2020 16:05 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
August 05, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 – – Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020 – – Xtampza ® ER Net Revenue...
Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
July 21, 2020 17:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday,...
Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work
June 17, 2020 17:09 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...